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Background: It has been shown that concomitant percutaneous trans-
luminal angioplasty (PTA) of above-the-knee (ATK) and below-the-knee
(BTK) arteries is highly beneficial for limb salvage in patients with critical
limb ischaemia (CLI), but few published studies have specifically investi-
gated outcomes in diabetic patients with CLI associated with isolated small
BTK-vessel disease. This study aimed to evaluate the long-term results of
successful PTA for limb salvage in such patients.
Materials and methods: From among the 634 patients with CLI in our
database, we retrospectively selected a consecutive series of 101 diabetics (16%)
with 107 critically ischaemic limbs (33 Rutherford 5 and 74 Rutherford 6) and
no critical ATK lesion, who underwent PTA on isolated BTK lesions.
Results: The limb salvage rate was 93% after a mean follow-up of
1048 525 days (2.9 1.4 years). Transcutaneous oxygen tension signifi-
cantly increased after 1 month (18.1 11.2 vs. 39.6 15.1; p 0.05). After
1 year, target-vessel re-stenosis had occurred in 42% of the non-amputated
limbs, nine patients (9%) had died because of medical conditions unrelated to
PTA and three patients had undergone repeat PTA for recurrent CLI.
Conclusions: In our selected patient population with ischaemic dia-
betic foot and isolated BTK lesions, a successful endovascular procedure led
to a high percentage of limb salvage at long-term follow-up.
A Randomised Open-Label Trial Comparing Long-term Sub-Cutane-
ous Low-Molecular-weight Heparin Compared with Oral-Anticoagu-
lant Therapy in the Treatment of Deep Venous Thrombosis
Romera A., Cairols M.A., Vila-Coll R., Martí X., Colomé E., Bonell A.,
Lapiedra O. Eur J Vasc Endovasc Surg 2009;xx:xx-xx.
Objective: To evaluate whether low-molecular-weight heparin
(LMWH) could be equally (or more) effective than oral anti-vitamin-K
agents (AVK) in the long-term treatment of deep venous thrombosis
(DVT).
Design: A randomised, open-label trial.
Material and methods: In this trial, 241 patients with symptomatic
proximal DVT of the lower limbs confirmed by duplex ultrasound scan were
included. After initial LMWH, patients received 6 months of treatment with
full therapeutic dosage of tinzaparin or acenocoumarol. The primary out-
come was the 12-month incidence of symptomatic recurrent venousReaders can access EJVES articles at http://intl.eResults: During the 12-month period, six patients (5%) of 119 who
received LMWH and 13 (10.7%) of 122 who received AVK had recurrent
VTE (p  0.11). In patients with cancer, recurrent VTE tended to be lower
in the LMWH group (two of 36 [5.5%]) vs. seven of 33 [21.2%]; p  0.06).
One major bleeding occurred in the LMWH group and three in the AVK
group. Venous re-canalisation increased significantly at 6 months (73.1% vs.
47.5%) and at 12 months (91.5% vs. 69.2%) in the LMWH group.
Conclusions: Tinzaparin was more effective than AVK in achieving
re-canalisation of leg thrombi. Long-term tinzaparin was at least as effica-
cious and safe as AVK for preventing recurrent VTE, especially in patients
with cancer.
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Results
Disselhoff B.C.V.M., Buskens E., Kelder J.C., der Kinderen D.J., Moll F.L.
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Background: Although endovenous laser ablation for varicose veins is
replacing surgical stripping, proper economic evaluation with adequate
follow-up in a randomised clinical trial is important for considered policy
decisions regarding the implementation of new techniques.
Methods: Data from a randomised controlled trial comparing cryos-
tripping and endovenous laser ablation in 120 patients were combined to
study Short Form (SF) 6D outcome, costs and cost-effectiveness 2 years after
treatment. Incremental cost per quality-adjusted life year (QALY) gained 2
years after treatment was calculated using different strategies, and uncer-
tainty was assessed with bootstrapping.
Results: Over the total study period, mean SF-6D scores improved
slightly from 0.78 at baseline to 0.80 at 2 years for patients who
underwent cryostripping and from 0.77 to 0.79 for patients who under-
went endovenous laser. QALY (SF-6D) was 1.59 in patients who under-
went cryostripping and 1.60 in patients who underwent endovenous laser
2 years after treatment. The costs of cryostripping and endovenous laser
per patient were €2651 and €2783, respectively. Bootstrapping indicated
that cryostripping was associated with an incremental cost-effectiveness
ratio of €32 per QALY gained. With regard to different strategies,
outpatient cryostripping was less costly and more effective 2 years after
treatment.
Conclusion: In this study, in terms of costs per QALY gained,
outpatient cryostripping appeared to be the dominant strategy, butthrombo-embolism (VTE). Duplex scans were performed at 6 and 12
months.
endovenous laser yielded comparable outcomes for a relatively little
additional cost.lsevierhealth.com/journals/ejvs/default.cfm
